A recent development has emerged as a dataset for tinnitus and deafness in Traditional Chinese Medicine (TCM), developed by YIDU TECH (02158) in collaboration with the Third Affiliated Hospital of Zhejiang Chinese Medical University, has officially obtained a data property rights registration certificate. This milestone offers a practical case study for the assetization of TCM-specific disease data and underscores the effectiveness of YIDU TECH's data governance and standardized dataset creation capabilities in the TCM field.
Clinical data in TCM is characterized by diverse diagnostic dimensions, fragmented treatment records, and mixed multimodal information, making standardized governance significantly more challenging than for common Western medical conditions. Since 2025, YIDU TECH has been deeply engaged with the Third Affiliated Hospital of Zhejiang Chinese Medical University, establishing a collaborative platform for clinical research. This partnership has laid the groundwork for three specialized disease areas, with a primary focus on tinnitus and deafness. A standardized disease-specific database has been built, integrating full-cycle information such as TCM syndrome differentiation, treatment methods, herbal prescriptions, acupuncture, modern hearing tests, and long-term follow-up, thereby structuring raw clinical data.
The project followed a clear progression: "specialized database construction, screening and processing, high-quality data integration, and property rights confirmation." Leveraging the hospital's clinical data, YIDU TECH applied its professional data governance technical capabilities, including cleansing, anonymization, standardized annotation, and quality assessment. This process resulted in a high-quality dataset with complete fields, standardized annotations, and reusability for research, meeting compliance standards for circulation. The entire process, from initiating data processing to completing property rights registration, took approximately one month, demonstrating YIDU TECH's mature data governance and efficient delivery capabilities.
The stable and efficient production of high-quality datasets relies on a systematic technical foundation. With over a decade of experience in medical data governance, YIDU TECH has developed a mature "high-quality dataset solution based on research-specific databases." This solution prioritizes traceability, high reliability, standardization, computability, and support for AI training and validation, all while adhering to strict data security and privacy protection regulations. The resulting datasets are applicable to various scenarios, including clinical decision-making, scientific research, and drug development.
As of March 31, 2026, YIDU TECH's proprietary "AI Medical Brain," YiduCore, has been authorized to process and analyze nearly 90 billion medical records. Its services cover over 12,000 medical institutions and have supported the creation of standardized datasets in more than 20 specialized disease areas. In collaboration with domain experts, the company has published monographs such as the "Leukemia Standard Dataset" and "Colorectal Cancer Standard Dataset," covering major disease areas like oncology, hematology, respiratory, and cardiovascular diseases. In terms of data compliance and circulation, the company has completed property rights registration for multiple high-quality datasets from various hospitals, establishing a mature and replicable paradigm for dataset construction.
YIDU TECH has also built a strong foundation in the digitalization of TCM, with its full-chain data governance capabilities closely aligned with TCM business logic. This enables the company to support multiple TCM institutions in unlocking the value of clinical data. Currently, YIDU TECH has partnered with the Jiangsu Provincial Hospital of Chinese Medicine to establish a research data center, focusing on key diseases to conduct clinical efficacy evaluation studies that align with TCM theory and international evidence-based standards. Additionally, in collaboration with the Zhejiang Provincial Key Laboratory of Kidney Essence Deficiency Syndrome, the company is supporting the translation of in-hospital TCM preparations into research outcomes and the development of new TCM drugs. This creates a comprehensive digital service capability covering specialized database construction, real-world studies, and innovation in TCM drug development.
Looking ahead, YIDU TECH plans to expand the construction of high-quality datasets for TCM-dominant diseases. Using secure and compliant data elements as a foundation, the company aims to empower diverse scenarios such as TCM evidence-based research, intelligent diagnostic and treatment development, and innovative chronic disease management models. This will drive the deep integration of traditional TCM with modern digital technology, assist medical institutions in activating the value of data assets, and inject digital momentum into the inheritance and innovation of TCM, as well as the construction of a Healthy China.